Commentary: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?
The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
The pharmaceutical industry stands to profit substantially from these drugs, which promise to bring in billions. Eli Lilly’s stock price jumped 6.7% after it announced positive results from a trial of one
